Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2013-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1301331110PMID 23818623PMCID PMC3718173
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• Abstract 1623: PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells.

  2013cited by this paper
• Bevacizumab in neoadjuvant treatment for breast cancer.

  2012cited by this paper
• Bevacizumab in ovarian cancer.

  2012cited by this paper
• Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs

  2012cited by this paper
• Proliferative and survival effects of PUMA promote angiogenesis.

  2012cited by this paper
• Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis

  2012cited by this paper
• Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

  2012cited by this paper
• Pazopanib and the treatment palette for soft-tissue sarcoma.

  2012cited by this paper
• Cold-induced activation of brown adipose tissue and adipose angiogenesis in mice

  2012cited by this paper
• Busulphan-Cyclophosphamide Cause Endothelial Injury, Remodeling of Resistance Arteries and Enhanced Expression of Endothelial Nitric Oxide Synthase

  2012cited by this paper
• Bevacizumab in ovarian cancer

  2012cited by this paper
• Bevacizumab in neoadjuvant treatment for breast cancer.

  2012cited by this paper
• Bevacizumab in Ovarian Cancer

  2012cited by this paper
• Opposing effects of circadian clock genes bmal1 and period2 in regulation of VEGF-dependent angiogenesis in developing zebrafish.

  2012cited by this paper
• A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.

  2012cited by this paper
• Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.

  2011cited by this paper
• Cardiovascular toxicity of anti-angiogenic drugs

  2011cited by this paper
• Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity

  2011cited by this paper
• Mouse corneal lymphangiogenesis model

  2011cited by this paper
• Taming glioblastoma by targeting angiogenesis: 3 years later.

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• Ramucirumab (IMC-1121B): a novel attack on angiogenesis.

  2010cited by this paper
• Bevacizumab toxicities and their management in ovarian cancer.

  2010cited by this paper
• Adipose angiogenesis: quantitative methods to study microvessel growth, regression and remodeling in vivo

  2010cited by this paper
• Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

  2010cited by this paper
• A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

  2010cited by this paper
• Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

  2009cited by this paper
• Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands

  2009cited by this paper
• VEGFR1–mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy

  2009cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• [Antiangiogenic agents and gastrointestinal cancers].

  2008cited by this paper
• Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

  2008cited by this paper
• Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

  2007cited by this paper
• Bevacizumab for non-small-cell lung cancer.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Bevacizumab for non-small-cell lung cancer.

  2007cited by this paper
• Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

  2006cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Endothelial cells and VEGF in vascular development

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004influential reference
• Bevacizumab in colorectal cancer.

  2004cited by this paper
• Bevacizumab in colorectal cancer.

  2004cited by this paper
• Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.

  2004cited by this paper
• Small GTP-Binding Protein Rac Is an Essential Mediator of Vascular Endothelial Growth Factor-Induced Endothelial Fenestrations and Vascular Permeability

  2003cited by this paper
• Bevacizumab in renal-cell cancer.

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia

  2002cited by this paper
• Identification of an angiogenic mitogen selective for endocrine gland endothelium

  2001cited by this paper
• Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression

  2001cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Vascular-specific growth factors and blood vessel formation

  2000cited by this paper
• Properties of Two VEGF Receptors, Flt‐1 and KDR, in Signal Transduction a

  2000cited by this paper
• Paracrine Control of the Adult Adrenal Cortex Vasculature by Vascular Endothelial Growth Factor

  2000cited by this paper
• Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat.

  1998cited by this paper
• Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

  1992cited by this paper
• Vascular endothelial growth factor is a secreted angiogenic mitogen.

  1989cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper
• Relation of capillary morphology to transport of fluid and large molecules: a review.

  1979cited by this paper
• Structural aspects of the permeability of the microvascular endothelium.

  1979cited by this paper
• Relation of capillary morphology to transport of fluid and large molecules: a review.

  1979cited by this paper
• Transplacental carcinogenesis by stilbestrol.

  1971cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• Mechanistic understanding of crosstalk between blood vessels and immunity and inflammation in diseases

  2026cites this paper
• Coviretinopathy: COVID-19-induced VEGF-dependent retinopathy.

  2026cites this paper
• Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency

  2026cites this paper
• PIEZO1 Mediates Apoptosis of Endothelial Cells via Enhancing HMGA2 Expression Under Simulated Microgravity

  2026cites this paper
• Multiscale profiling of tyrosine kinase inhibitor cardiotoxicity reveals mechanosensitive ion channel PIEZO1 as cardioprotective.

  2025cites this paper
• Impact of Antivascular Endothelial Growth Factor Therapy in Chronic Subdural Hematoma Patients: A Propensity-Matched Multi-Institutional Cohort Study

  2025cites this paper
• Obesity drives depot-specific vascular remodeling in male white adipose tissue

  2025cites this paper
• Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives

  2025cites this paper
• Angiopoietin–TIE2 feedforward circuit promotes PIK3CA-driven venous malformations

  2025cites this paper
• Fatal portal vein thrombosis following combination therapy with atezolizumab plus bevacizumab for hepatocellular carcinoma: an autopsy case report

  2025cites this paper
• Effects of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol levels in patients with metastatic renal cell carcinoma: a retrospective study

  2025cites this paper
• Research Progress Regarding the Use of Single-Cell Sequencing Technology in Analyzing Tumor Endothelial Cell Pathophysiology

  2025cites this paper
• Celebrating the 1945 JNCI pioneering contribution to antiangiogenic therapy for cancer.

  2024cites this paper
• VEGF—Virus Interactions: Pathogenic Mechanisms and Therapeutic Applications

  2024cites this paper
• Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies.

  2024cites this paper
• Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody

  2024cites this paper
• Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer

  2024cites this paper
• A real-world drug safety surveillance study of lenvatinib from the FAERS database

  2024cites this paper
• Effective Prevention and Treatment of Acute Leukemias in Mice by Activation of Thermogenic Adipose Tissues

  2024cites this paper
• Macrophages preserve endothelial cell specialization in the adrenal gland to modulate aldosterone secretion and blood pressure.

  2024cites this paper
• Blood–brain barrier disruption and edema formation due to prolonged starvation in wild-type mice

  2024cites this paper
• Nanotherapy to Reshape the Tumor Microenvironment: A New Strategy for Prostate Cancer Treatment

  2024cites this paper
• Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives

  2024cites this paper
• A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma

  2024cites this paper
• Up-to-date molecular medicine strategies for management of ocular surface neovascularization.

  2023cites this paper
• Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy

  2023cites this paper
• Understanding tumour endothelial cell heterogeneity and function from single-cell omics

  2023cites this paper
• Intestinal Lymphatic Dysfunction in Kidney Disease

  2023cites this paper
• Targeting angiogenesis in oncology, ophthalmology and beyond

  2023cites this paper
• Mechanisms and functions of intestinal vascular specialization

  2023cites this paper
• ADAMTS18+ villus tip telocytes maintain a polarized VEGFA signaling domain and fenestrations in nutrient-absorbing intestinal blood vessels

  2022cites this paper
• Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy

  2022cites this paper
• Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth

  2022cites this paper
• FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis

  2022cites this paper
• MORTALIN-Ca2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma.

  2022cites this paper
• The impact of VEGF on cancer metastasis and systemic disease.

  2022cites this paper
• Tumours modulate the systemic vascular response to anti‐angiogenic therapy

  2022cites this paper
• Comparative ligandomics implicates secretogranin III as a disease‐restricted angiogenic factor in laser‐induced choroidal neovascularization

  2022cites this paper
• Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance

  2022cites this paper
• COVID-19 instigates adipose browning and atrophy through VEGF in small mammals

  2022cites this paper
• Blood vessels in fat tissues and vasculature-derived signals in controlling lipid metabolism and metabolic disease

  2022cites this paper
• Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting

  2022cites this paper
• Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma

  2022cites this paper
• Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism

  2022cites this paper
• EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function

  2021cites this paper
• Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy

  2021cites this paper
• Inhibitory effects of icotinib combined with antiangiogenic drugs in human non‐small cell lung cancer xenograft models are better than single target drugs

  2021cites this paper
• Focus on ferroptosis, pyroptosis, apoptosis and autophagy of vascular endothelial cells to the strategic targets for the treatment of atherosclerosis.

  2021cites this paper
• Interplay between Gut Lymphatic Vessels and Microbiota

  2021cites this paper
• Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event

  2021cites this paper
• Vascular rejuvenation is geroprotective

  2021cites this paper
• Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy

  2021cites this paper
• Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma

  2021cites this paper
• Understanding the Pathogenesis of Gestational Hypothyroidism

  2021cites this paper
• Tumors modulate fenestrated vascular beds and host endocrine status

  2021cites this paper
• Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

  2021cites this paper
• Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes

  2021influential citation
• Nanotechnology: revolutionizing the delivery of drugs to treat age-related macular degeneration

  2021cites this paper
• Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity

  2021cites this paper
• Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma

  2021cites this paper
• DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer

  2020cites this paper
• Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events

  2020cites this paper
• Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma

  2020cites this paper
• Photoreceptor Degeneration Accompanies Vascular Changes in a Zebrafish Model of Diabetic Retinopathy

  2020cites this paper
• Endothelial-specific YY1 governs sprouting angiogenesis through directly interacting with RBPJ

  2020cites this paper
• Tubulin carboxypeptidase activity of vasohibin-1 inhibits angiogenesis by interfering with endocytosis and trafficking of pro-angiogenic factor receptors

  2020cites this paper
• Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma

  2020cites this paper
• The role of CD44 in pathological angiogenesis

  2020cites this paper
• Tyrosine Kinase Inhibitors’ Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer

  2020cites this paper
• Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling

  2019cites this paper
• Talin-Dependent Integrin Activation Regulates VE-Cadherin Localization and Endothelial Cell Barrier Function

  2019cites this paper
• The effect of intrathyroidal versus intraperitoneal bevacizumab on thyroid volume and vasculature flow in a rat model.

  2019cites this paper
• Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.

  2019cites this paper
• Growth factor signaling pathways in vascular development and disease

  2019cites this paper
• Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions

  2019cites this paper
• Endothelial life discontinues without Erk

  2019cites this paper
• Biochemical and Conformational Characterization of Recombinant VEGFR2 Domain 7

  2019cites this paper
• Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor

  2019cites this paper
• Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy.

  2019cites this paper
• Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.

  2018cites this paper
• Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling

  2018cites this paper
• Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning

  2018influential citation
• Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy

  2018cites this paper
• Emerging Functions of Regulatory T Cells in Tissue Homeostasis

  2018cites this paper
• Dual roles of endothelial FGF-2–FGFR1–PDGF-BB and perivascular FGF-2–FGFR2–PDGFRβ signaling pathways in tumor vascular remodeling

  2018cites this paper
• VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis

  2017cites this paper
• Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel

  2017cites this paper
• Intestinal lymphatic vasculature: structure, mechanisms and functions

  2017cites this paper
• Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma

  2017cites this paper
• High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation

  2017cites this paper
• Endothelial cell apoptosis in angiogenesis and vessel regression

  2017influential citation
• Correlative Imaging of the Murine Hind Limb Vasculature and Muscle Tissue by MicroCT and Light Microscopy

  2017cites this paper
• Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy

  2017cites this paper
• Reversing the polarization of tumor‐associated macrophages inhibits tumor metastasis

  2017cites this paper
• Thyroid disease in pregnancy: new insights in diagnosis and clinical management

  2017cites this paper
• Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production

  2017cites this paper
• Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology

  2017cites this paper
• PPARG is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target

  2017cites this paper
• Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)

  2016cites this paper
• Pericyte–fibroblast transition promotes tumor growth and metastasis

  2016cites this paper